Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00787852 · ClinicalTrials.gov registry record · Phase 1
A Study of Dasatinib With Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer (NSCLC)
A Phase 1 study, sponsored by Brown University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
NCT00787852 is a Phase 1 study that was terminated before completion, run by Brown University. The registered enrollment target is 11 participants.
The verdict
NCT00787852, a Phase 1 study, was terminated before completion, sponsored by Brown University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate if a maximum dose of 100 mg of dasatinib with concurrent chemoradiation can be tolerated in patients with chemotherapy naive stage III NSCLC in separate cohorts of locally advanced and potentially resectable disease.
Interventions
- DRUG Group 1: Radiation, Paclitaxel,Carbo, Dasatinib days 1-47
- DRUG Group 2: Radiation, Paclitaxel, Carbo, Dasatinib days 1-38
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2009-03 |
| Est. Completion | 2011-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00787852
The ClinicalTrials.gov registry entry for NCT00787852 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brown University, which has 231 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Group 1: Radiation, Paclitaxel,Carbo, Dasatinib days 1-47 is the first listed.
NCT00787852 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00787852 about?
NCT00787852 is a clinical study titled "A Study of Dasatinib With Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer (NSCLC)". The purpose of this study is to evaluate if a maximum dose of 100 mg of dasatinib with concurrent chemoradiation can be tolerated in patients with chemotherapy naive stage III NSCLC in separate cohorts of locally advanced and potentially resectable disease.
What is the current status of trial NCT00787852?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2009-03. Estimated completion is 2011-12.
What interventions are being tested in trial NCT00787852?
The interventions under investigation include: Group 1: Radiation, Paclitaxel,Carbo, Dasatinib days 1-47 (DRUG), Group 2: Radiation, Paclitaxel, Carbo, Dasatinib days 1-38 (DRUG).
Who is sponsoring clinical trial NCT00787852?
This trial is sponsored by Brown University, which has 231 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.